Compare Futu Holdings Ltd (FUTU) vs 10X Genomics Inc (TXG) Price & Performance

FUTU trades at $98.2, up 0.07% on the day, with a bullish technical signal but mixed earnings history including a Q1 2026 miss. The company shows strong fundamentals with 2025 revenue of $22.85B, net income margin of 49.62%, and robust cash flow. However, multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The outlook is clouded by legal risks despite solid profitability and analyst support (58% buy ratings). Investment opportunity hinges on resolution of regulatory allegations, while key risks include potential financial penalties and reputational damage from ongoing litigation.

10x Genomics (TXG) trades at $42.56, down 7.07% today, with mixed technical signals showing bullish moving averages but overbought RSI levels. The company demonstrates strong revenue stability around $640M annually and improving profitability trends, with net losses narrowing significantly from -$255M in 2023 to -$44M in 2025. Recent strategic moves include the Proteintech Genomics acquisition and Cleveland Clinic collaboration to expand multiomics capabilities.

While the company shows promising margin improvement and strategic growth initiatives, investors face valuation concerns with elevated P/S and EV/EBITDA ratios. The mixed analyst sentiment (45% buy, 50% hold) and consensus price target below current levels suggest cautious optimism. Key risks include ongoing profitability challenges and competitive pressures in the life sciences tools market.